Endoglin (CD 105) is expressed on endothelial cells in the primary central nervous system lymphomas and correlates with survival

Journal of Neuro-Oncology

Volumn 82, Issue 3, 2007, Pages 249-256

  Sugita, Yasuo ^a,c   Takase, Yukari ^a   Mori, Daisuke ^a   Tokunaga, Osamu ^a   Nakashima, Akihiko ^b   Shigemori, Minoru ^c  

^a SAGA UNIVERSITY   (Japan)

^b Saisekai Fukuoka General Hospital   (Japan)

^c KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

CD105 (endoglin); CD34; Central nervous system lymphomas; Neoangiogenesis; Prognosis

Indexed keywords

CD34 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ENDOGLIN; METHOTREXATE; MONOCLONAL ANTIBODY; PREDNISONE; VINCRISTINE;

ADULT; AGED; ANGIOGENESIS; ANTIGEN EXPRESSION; ARTICLE; BRAIN CANCER; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG MEGADOSE; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPHOMA; MALE; MICROVASCULATURE; PARENCHYMA; PROGNOSIS; RELIABILITY; SURVIVAL RATE;

AGED; AGED, 80 AND OVER; ANTIGENS, CD; ANTIGENS, CD34; CENTRAL NERVOUS SYSTEM NEOPLASMS; DISEASE PROGRESSION; ENDOTHELIAL CELLS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; LYMPHOMA; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, CELL SURFACE; TUMOR MARKERS, BIOLOGICAL;

EID: 34247183623     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-006-9281-3     Document Type: Article

References (27)

1. Chang C-C, Kampalath B, Schultz C, Bunyi-Teopengco E, Logan B, Eshoa C, Dincer AP, Perkins SL (2003) Expression of p53, c-Myc, or Bcl-6 suggests a poor prognosis in primary central nervous system diffuse large B-cell lymphoma among immunocompetent individuals. Arch Pathol Lab Med 127:208-212
2. Paulus W, Jellinger K, Morgello S, Deckert-Schluter M (2000) Malignant lymphomas. In: Kleihues P, Cavenee WK (eds) Pathology and genetics of tumours of the nervous system. International Agency for Research on Cancer Press, Lyon, pp 198-203
3. Sugita Y, Tokunaga O, Nakashima A, Shigemori M (2004) SHP-1 expression in primary central nervous system B-cell lymphomas in immunocompetent patients reflects maturation stage of normal B cell counterparts. Pathol Int 54:659-666
4. Arai M, Sasaki S, Saito N, Nakazato Y (2005) Immunohistochemical analysis of cleaved caspase-3 detects high level of apoptosis frequently in diffuse large B-cell lymphomas of the central nervous system. Pathol Int 55:122-129
5. Bellamy WT, Richter L, Frutiger Y, Grogan TM (1999) Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res 59:728-733
6. Bodey B, Bodey JR B, Siegel SE, Kaiser HE (1998) Upregulation of endoglin (CD105) expression during childhood brain tumor-related angiogenesis. Anti-angiogenic therapy. Anticancer Res 18:1485-1500
7. Choi WWL, Lewis MM, Lawson D, Yin-Goen Q, Birdsong GG, Cotsonis GA, Cohen C, Young AN (2005) Angiogenic and lymphangiogenic microvessel density in breast carcinoma: Correlation with clinicopathologic parameters and VEGF-family gene expression. Mod Pathol 18:143-152
8. Dales JP, Garcia S, Carpentier S, Andrac L, Ramuz O, Lavaut MN, Allasia C, Bonnier P, Charpin C (2004) Long-term prognostic significance of neoangiogenesis in breast carcinomas: Comparison of Tie-2/Tek, CD105, and CD 31 immunocytochemical expression. Hum Pathol 35:176-183
9. Duarte IG, Bufkin BL, Pennington MF, Gall AA, Cohen C, Kosinski AS, Mansour KA, Miller JI (1998) Angiogenesis as a predictor of survival after surgical resection for stage I non-small-cell lung cancer. J Thorac Cardiovasc Surg 115:652-658
10. Giatromanolaki A, Koukourakis M, O'Byrne K, Fox S, Whitehouse R, Talbot DC, Harris AL, Gatter KC (1996) Prognostic value of angiogenesis in operable non-small cell lung cancer. J Pathol 179:80-88
11. Hedvat CV, Comenzo RL, Teruya-Feldstein J, Olshen AB, Ely SA, Osman K, Zhang Y, Kalakonda N, Nimer SD (2003) Insights into extramedullary tumour cell growth revealed by expression profiling of human plasmacytomas and multiple myeloma. Br J Hematol 122:728-744
12. Houthoff HJ, Poppema S, Ebels EJ, Elema JD (1978) Intracranial malignant lymphomas. A morphologic and immunocytologic study of twenty cases. Acta Neuropathol (Ber) 44:203-210
13. Minhajat R, Mori D, Yamasaki F, Sugita Y, Satoh T, Tokunaga O (2005) Endoglin (CD 105) expression in angiogenesis of colon cancer; analysis using tissue microarrays and comparison with other endothelial markers. Vichows Arch 22:1-8
14. Okada K, Satoh T, Fujimoto K, Tokunaga O (2004) Interaction between morphology and angiogenesis in human early colorectal cancers. Pathol Int 54:490-497
15. Rubenstein J, Fischbein N, Aldape K, Burton E, Shuman M (2002) Hemorrhage and VEGF expression in a case of primary CNS lymphoma. J Neuro-Oncol 58:53-56
16. Saad RS, EL-Gohary Y, Memari E, Liu YL, Silverman JF (2005) Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in esophageal adenocarcinoma. Hum Pathol 36:955-961
17. Salven P, Orpana A, Teerenhovi L, Joensuu H (2000) Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: A single-institution study of 200 patients. Blood 96:3712-3718
18. Santos L, Costa C, Pereira S, Koch M, Amaro T, Cardoso F, Guimaraes T, Bento MJ, Lobo F, Pinto S, Lopes C (2003) Neovascularisation is a prognostic factor of early recurrence in T1/G2 urothelial bladder tumours. Ann Oncol 14:1419-1424
19. Takahashi N, Haba A, Matsuno F, Seon BK (2001) Antiangogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies and synergy between anti-endoglin antibody and cyclophosphamide. Cancer Res 61:7846-7854
20. Tanaka F, Otake Y, Yanagiha K, Kawano Y, Miyahara R, Li M, Ishikawa S, Wada H (2003) Correlation between apoptotic index and angiogenesis in non-small cell lung cancer: Comparison between CD105 and CD34 as a marker of angiogenesis. Lung Cancer 39:289-296
21. Yamamoto S, Yasui W, Kitadai Y, Yokozaki H, Haruma K, Kajiyama G, Tahara E (1998) Expression of vascular endothelial growth factor in human gastric carcinomas. Pathol Int 48:499-506
22. Yao Y, Kubota T, Takeuchi H, Sato K (2005) Prognostic significance of microvessel density determined by an anti-CD105/endoglin monoclonal antibody in astrocytic tumors: Comparison with an anti-CD31 monoclonal antibody. Neuropathology 25:201-206
23. Zhao W-L, Mourah S, Mounier N, Lebouef C, Daneshpousy ME, Legres L, Meignin V, Oksenhendler E, Le Maignin C, Calvo F, Briere J, Gisselbrecht C, Janin A (2004) Vascular endothelial growth factor-A is expressed both on lymphoma cells and endothelial cells in angioimmunoblastic T-cell lymphoma and related lymphoma progression. Lab Invest 84:1512-1519
24. Stewart M, Talks K, Leek R, Turley H, Pezzella F, Harris A, Gatter K (2002) Expression of angiogenic factors and hypoxia inducible HIF 1, HIF2, and CA IX in non-Hodgkin's lymphoma. Histopathology 40:253-260
25. Roser F, Saini M, Meliss R, Ostertag H, Samii M, Bellinzona M (2004) Apoptosis, vascularity, and proliferation in primary central nervous system lymphomas: A histopathological study. Surg Neurol 62:393-399
26. Duff SE, LI C, Garland JM, Kumar S (2003) CD105 is important for angiogenesis: Evidence and potential applications. FASEB 17:984-992
27. Russel DS, Rubinstein LJ (1989) Primary cerebral lymphomas. In: Russel DS, Rubinstein LJ (eds) Pathology of tumours of the nervous system. Williams & Wilkins, Baltimore, pp 592-608